Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Lincolnton › NPI 1326088139
Hospital

The Charlotte-Mecklenburg Hospital Authority

The Charlotte-Mecklenburg Hospital Authority was paid $20.69M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.

33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
LINCOLNTON, NC 28092
33aNPI1326088139assigned 06/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.69M
24GClaims318,402
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in North Carolina

Rank by total paid#27 of 92
Median peer was paid$11.47M
This provider vs. median1.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201844,148$2.09M
201945,714$2.31M
202036,622$1.52M
202147,143$3.04M
202248,549$3.85M
202347,887$4.03M
2024incomplete48,339$3.85M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 31% 30,755 28,743 $6.44M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 30% 28,495 26,943 $6.19M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 13% 13,105 12,218 $2.59M
41899 Unlisted procedure, dentoalveolar structures 6.2% 908 875 $1.28M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 3.2% 4,232 3,926 $654K
74177 Computed tomography, abdomen and pelvis; with contrast material 2.3% 1,222 1,143 $486K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.9% 11,364 10,418 $388K
80053 Comprehensive metabolic panel 1.1% 26,999 24,545 $230K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.1% 13,253 12,310 $222K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 1.0% 10,029 8,376 $212K
71046 Radiologic examination, chest; 2 views 1.0% 6,565 6,239 $208K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 22,544 20,288 $167K
116 more codes
71045 Radiologic examination, chest; single view <1% 5,640 $142K
70450 Computed tomography, head or brain; without contrast material <1% 960 $138K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 743 $130K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,259 $110K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,371 $108K
81025 <1% 9,247 $68K
J3490 Unclassified drugs <1% 30,043 $62K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 134 $59K
85027 <1% 8,768 $53K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 997 $52K
83690 <1% 7,218 $49K
62323 <1% 411 $45K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 179 $44K
84484 <1% 5,252 $43K
96375 Therapeutic injection; each additional sequential IV push <1% 7,664 $41K
81001 <1% 10,272 $34K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,723 $27K
59025 Fetal non-stress test <1% 320 $25K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 936 $24K
80048 Basic metabolic panel (calcium, ionized) <1% 2,609 $22K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 1,516 $21K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 326 $21K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 846 $20K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 74 $20K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 331 $15K
0002A <1% 273 $14K
0001A <1% 271 $14K
J8499 Prescription drug, oral, non chemotherapeutic, nos <1% 10,373 $13K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 896 $12K
81003 <1% 4,735 $11K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 405 $10K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,944 $10K
82728 <1% 914 $10K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 39 $10K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 208 $10K
80050 General health panel <1% 138 $8K
80061 Lipid panel <1% 347 $8K
96361 Intravenous infusion, hydration; each additional hour <1% 1,957 $8K
J2704 Injection, propofol, 10 mg <1% 2,898 $6K
82803 <1% 432 $6K
J2270 Injection, morphine sulfate, up to 10 mg <1% 2,526 $5K
87086 Culture, bacterial; quantitative colony count, urine <1% 593 $5K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 754 $5K
71275 Computed tomographic angiography, chest, with contrast material <1% 12 $5K
64493 <1% 14 $5K
87430 <1% 283 $4K
84443 Thyroid stimulating hormone (TSH) <1% 167 $4K
83605 <1% 471 $4K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,992 $3K
87070 <1% 267 $3K
84466 <1% 393 $3K
83735 <1% 425 $3K
87581 <1% 74 $3K
87486 <1% 74 $3K
G0378 Hospital observation service, per hour <1% 38 $3K
83036 Hemoglobin; glycosylated (A1C) <1% 189 $3K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 1,801 $3K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,064 $3K
20553 <1% 132 $2K
64483 <1% 15 $2K
64494 <1% 14 $2K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 12 $2K
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 720 $2K
83880 <1% 47 $2K
83540 <1% 407 $2K
84439 <1% 115 $2K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 12 $1K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 90 $1K
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 942 $1K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 79 $999.60
80320 <1% 27 $948.22
76942 <1% 50 $846.99
94060 <1% 14 $773.45
73630 <1% 28 $730.26
0011A <1% 12 $715.00
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 396 $706.85
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 28 $672.32
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 28 $672.32
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 553 $617.12
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 44 $608.98
94729 <1% 14 $602.13
0012A <1% 13 $585.00
73130 <1% 12 $553.92
94618 <1% 13 $535.69
85379 <1% 43 $466.83
Q3014 Telehealth originating site facility fee <1% 20 $455.29
94726 <1% 14 $448.18
86140 <1% 58 $425.35
82962 <1% 166 $412.72
80143 <1% 12 $377.90
20610 <1% 15 $365.37
87081 <1% 52 $330.28
87420 <1% 14 $271.91
82607 <1% 27 $267.62
J8597 Antiemetic drug, oral, not otherwise specified <1% 288 $210.34
73562 <1% 12 $200.16
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 305 $188.95
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 80 $150.56
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 104 $137.33
85652 <1% 31 $135.23
Q9965 Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml <1% 48 $127.01
99199 Unlisted special service, procedure or report <1% 15 $115.00
J8540 Dexamethasone, oral, 0.25 mg <1% 190 $110.19
96376 <1% 30 $98.21
J3010 Injection, fentanyl citrate, 0.1 mg <1% 37 $80.75
87210 <1% 13 $47.50
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 24 $42.38
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 25 $41.70
J2550 Injection, promethazine hcl, up to 50 mg <1% 31 $39.24
J1030 Injection, methylprednisolone acetate, 40 mg <1% 13 $34.17
J2004 Injection, lidocaine hcl with epinephrine, 1 mg <1% 12 $18.50
91300 0% 553 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 29 $0.00
A9270 Non-covered item or service 0% 1,009 $0.00
91301 0% 25 $0.00
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMORRIS, JARRETT (CONTROLLER)